Prana Biotechnology (ATHE)
(Delayed Data from NSDQ)
$2.00 USD
-0.02 (-0.99%)
Updated May 17, 2024 03:59 PM ET
After-Market: $2.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ATHE 2.00 -0.02(-0.99%)
Will ATHE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ATHE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATHE
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?
ATHE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ATHE
12 Health Care Stocks Moving In Friday's After-Market Session
Alterity’s ATH434 Advances in Phase 2 MSA Trial
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
Alterity announces DMC recommends to continue Phase 2 study of ATH434-201
12 Health Care Stocks Moving In Friday's Pre-Market Session